Persistent Epithelial Defect Management Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the persistent epithelial defect management market grown over the years?
The market for managing persistent epithelial defects has seen swift expansion in recent years. The market value is expected to escalate from $7.92 billion in 2024 to $9.29 billion in 2025, projecting a compound annual growth rate (CAGR) of 17.3%. The surge during the historic period is due to a rise in research activities, a growing demand in hospitals, increased instances of ocular surface disorders, surge in eye disorder cases, and an aging population.
What Is the forecasted market size and growth rate for the persistent epithelial defect management market?
The market size for managing persistent epithelial defects is likely to experience fast-paced expansion in the forthcoming years. The expected growth rate is estimated to be $17.35 billion in 2029, with a compound annual growth rate (CAGR) of 16.9%. The increase during the prediction period can be attributed to factors like increased partnerships and collaborations, improved awareness and education, emphasis on value-based care, rising occurrences of ailments such as diabetes and hypertension, and prompt intervention and management. The forecast period will also see major trends such as technological advancements, escalating demand for novel treatment options, advanced treatment procedures, access to cutting-edge surgical tools and techniques, and innovative medications.
Get your persistent epithelial defect management market report here!
What are the major factors driving growth in the persistent epithelial defect management market?
The escalation in incidences of eye-related health conditions is anticipated to spur the persistent epithelial defect management market’s expansion in the future. Such eye diseases encompass an extensive set of disorders impacting the eye’s structure, function, or health contributing to vision loss, discomfort, or possibly blindness. The upswing in such ailments is influenced by multiple factors like the ageing demographic, extended screen exposure, and changes in the environment. Administration of persistent epithelial defect is critical in managing these eye diseases—it facilitates healing, diminishes inflammation, and deters complications like infection or scarring. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in December 2024 that the overall combined prevalence for childhood myopia stood at 5.23% in 2023, with a markedly raised rate in females (4.90%) compared to males (3.94%). Therefore, the rise in eye disorders necessitates the expansion of the persistent epithelial defect management market. Also, the surge in eye surgeries is propelling the persistent epithelial defect management market growth. These surgeries are medical interventions performed on the eye to rectify vision inaccuracies, treat illnesses, or mend injuries. This surge is due to factors such as the rising incidences of eye diseases like cataracts and glaucoma, progress in surgical methods, and an increasing trend toward minimally invasive procedures. Persistent epithelial defect management improves the efficacy of eye surgeries by accelerating corneal healing, minimizing complications, and enhancing visual outcomes through focused treatments that aid in epithelial regeneration. For instance, the Eye Bank Association of America, a US-based transplant association, reported in 2023 that domestic keratoplasty procedures had increased by 2.7%, from 49,597 in 2022 to 50,925 in 2023. Therefore, the increasing frequency of eye surgeries serves as a catalyst for the growth of the persistent epithelial defect management market.
What key areas define the segmentation of the global persistent epithelial defect management Market?
The persistent epithelial defect management market covered in this report is segmented –
1) By Disease Type: Epithalial Or Limbal, Inflammatory Disease, Neurotrophic Disease, Other Disease Types
2) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Hospitals
3) By End User: Hospital Or Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users
Subsegments:
1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD), Limbal Transplantation, Conjunctival Transplantation
2) By Inflammatory Disease: Dry Eye Syndrome, Allergic Conjunctivitis, Uveitis
3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis, Diabetic Neuropathy, Neurotrophic Keratopathy
4) By Other Disease Types: Chemical Burns, Trauma-Induced Defects, Congenital Corneal Opacities
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21256&type=smp
What are the top market players propelling the growth of the persistent epithelial defect management industry?
Major companies operating in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompé Farmaceutici S.p.A., Lumenis Ltd., TissueTech Inc., Ocular Therapeutix Inc., Oculus Surgical Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc.
How are evolving market trends shaping persistent epithelial defect management Strategies?
Prominent enterprises in the persistent epithelial defect management market are concentrating on the development of unique therapies like secretome therapy, in order to quicken healing and enhance the results of treatment for persistent epithelial defects. Secretome therapy involves the use of cellularly secreted bioactive substances such as proteins, lipids, and extracellular vesicles for tissue restoration, immune system modulation, and the treatment of numerous diseases. For example, in April 2023, US-based Kala Pharmaceuticals Inc., got a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for KPI-012, an innovative human MSC-S therapy for persistent corneal epithelial defect. The multifaceted mechanism of the drug seeks to tackle all fundamental causes of persistent epithelial defect management by enhancing corneal healing using bioactive elements, such as growth factors, protease inhibitors and neurotrophic factors.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21256
What regions are dominating the persistent epithelial defect management market growth?
North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Osteoarthritis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report
Rheumatoid Arthritis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report
Transthyretin Amyloidosis Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
